醋酸阿比特龙在转移性去势抵抗性前列腺癌患者中的心血管安全性：前瞻性评估。
Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.
机构信息
Medical Oncology I, Fondazione Del Piemonte Per l'Oncologia, IRCCS Candiolo, Turin, Italy.
Medical Oncology, ASL CN 2, Alba e Bra, Cuneo, Italy.
出版信息
Future Oncol. 2018 Feb;14(5):443-448. doi: 10.2217/fon-2017-0385. Epub 2018 Jan 10.
AIM
The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors.
PATIENTS & METHODS: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities.
RESULTS
Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively.
CONCLUSION
AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.
目的
本研究旨在评估伴有心血管合并症或冠状动脉疾病（CAD）危险因素的转移性去势抵抗性前列腺癌（mCRPC）患者使用醋酸阿比特龙（AA）的心脏毒性。
患者与方法
我们前瞻性分析了接受 AA 治疗的患者，以评估心脏毒性发作与 CAD 危险因素或心血管合并症之间的相关性。
结果
共纳入 87 例患者，中位治疗时间为 9 个月（1-44）。基线时，84 例患者（96%）存在 CAD 危险因素。治疗期间，4 例患者（4%）发生高血压，26 例患者（30%）原有高血压恶化。左心室射血分数中位数分别为治疗前 64%和治疗后 63%。
结论
AA 似乎对伴有心血管合并症或 CAD 危险因素的患者是安全的。
Zotero 插件